Tags:
create new tag
, view all tags, tagging instructions

All Graphics Form Entries

Return to Statistical Graphics Home

All Graphs

Title Contributor/Email Reference Image Graph Type
Basic Survival Plot Mat Soukup (email: Mat.Soukup@fda.hhs.gov) survplotRMS_200.jpg Survival Plot
Boxplot of Two Treatment Groups Mat Soukup (email: Mat.Soukup@fda.hhs.gov) boxplotbasic_200.jpg Boxplot
Change from Baseline by Baseline: Categorical QTc Analysis Rich Anziano (richard.j.anziano@pfizer.com)
Max Cherny (Max.2.Cherny@gsk.com)
3_Baseline_QTc_hr1_200.png Scatterplot
Cumulative Incidence for Alanine Aminotransferase (ALT): Elevations > 3 Times the Upper Limit of Normal Robert Gordon (rgordon2@its.jnj.com) GordonCumulIncidencePlot_200.png  
Depicting Phase 2 Efficacy Results Mat Soukup (email: Mat.Soukup@fda.hhs.gov) DepictingPhaseTwo_Referemce_200.jpg Scatterplot
Diagnostic Plot of Linear Model Mat Soukup (email: Mat.Soukup@fda.hhs.gov) lmplot_reference_200.png Scatterplot
Distribution of Alanine Aminotransferase (ALT) by Time and Treatment Robert Gordon (rgordon2@its.jnj.com)
Gordon_Distribution_ALT_200.png Boxplot
Dotplot of Primary SOC Mat Soukup (email: Mat.Soukup@fda.hhs.gov)
Sanjay Matange (email: Sanjay.Matange@sas.com)
DotplotSOC_reference_200.png Dotplot
EG QTc Longitudinal Trend jianminlong@merck.com Long_QTc_longitudinal_200.png Line Plot, Scatterplot, Other
Efficacy Across Sites Mat Soukup (email: Mat.Soukup@fda.hhs.gov) efficacybysite_Referemce_200.jpg Scatterplot
Efficacy by Subgroup Mat Soukup (email: Mat.Soukup@fda.hhs.gov) plottable_referemce_200.jpg Scatterplot
Efficacy of T4N5 The Lancet Data - Code Expands Mat Soukup (email: Mat.Soukup@fda.hhs.gov) LancetEfficacy_reference_200.jpg Scatterplot
Forest Plot of Hazard Ratios by Patient Subgroups Sanjay Matange (email: Sanjay.Matange@sas.com) Matange_ForestPlot_Pocock_200.png Forest Plot
Frequency Plot of the Change from Baseline in Alanine Aminotransferase by Visit Robert Gordon (rgordon2@its.jnj.com) Gordon_FreqPlot_200.png  
HPA Axis Suppression Mat Soukup (email: Mat.Soukup@fda.hhs.gov) HPAaxis_Reference_200.jpg Scatterplot
Heat map max.2.cherny@gsk.com
Sanjay Matange (email: Sanjay.Matange@sas.com)
Cherny_GGPLOT_Benefit_Risk_200.png  
Individual QTc display A. Paredes, Antonio.Paredes@fda.hhs.gov
Max Cherny: Max2Cherny@gsk.com
Cherny_Rplot2_200.png  
Lab Parameter Shift Plots, Baseline vs. Study Robert Gordon (rgordon2@its.jnj.com) Gordon_Shift_Plot_200.png Scatterplot
Lab Shift Plots: Baseline versus Maximum Susan Duke (susan.p.duke@gsk.com)
Max Cherny (Max.2.Cherny@gsk.com)
Cherny_t2t_200.png Scatterplot
Liver Function Tests by Trial Day: At Risk Subjects Robert Gordon (rgordon2@its.jnj.com) Gordon_LFTTrialDay_200.png Line Plot
Liver Test Safety Panel Over Time, Baseline vs. On-study Robert Gordon (rgordon2@its.jnj.com)
Gordon_LiverTestSafety_200.png Scatterplot
Local Reactions over Time Mat Soukup (email: Mat.Soukup@fda.hhs.gov) local_reference_200.png Scatterplot
Mean (and Mean Difference) of ALT (Alanine Aminotransferase) by Treatment : Profile Over Time Robert Gordon (rgordon2@its.jnj.com) Fig1_MeanALT_200.jpg Line Plot
Most Frequent On-Therapy AE Sorted by Risk Difference FrankHarrell Figure11_AE_200.png Dotplot
P-risk (Risk Difference) Plot of Treatment Emergent Adverse Events at PT Level Qi Jiang (email: Qjiang@amgen.com)
SAS code contributed by Haijun Ma and Jun Wei
Jiang_AE_Risk_200.png Volcano Plots
Profile Plot: Mean QTc by Time and Treatment Rich Anziano (richard.j.anziano@pfizer.com)
Max Cherny (Max.2.Cherny@gsk.com)
QTc_Profiles_r200.png Line Plot
QT Correction Comparison R.J. Anziano, Richard.J.Anziano@Pfizer.com DRAFT_Comparison_QT_200.png Scatterplot
Reports by SOC Mat Soukup (email: Mat.Soukup@fda.hhs.gov) ReportsBySOC_referemce_200.jpg  
Scatter Plot of Maximum Transaminase versus Maximum Total Bilirubin Robert Gordon (rgordon2@its.jnj.com) MaxBilirubin_200.png Scatterplot
Scatterplot Conditioned on Race Mat Soukup (email: Mat.Soukup@fda.hhs.gov) scattertrellis_reference_200.jpg Scatterplot
Scatterplot w/ Density and Smoothed Regression Mat Soukup (email: Mat.Soukup@fda.hhs.gov) scatterdensity_reference_200.jpg Scatterplot
Sensitivity Analysis of Missing Data Mat Soukup (email: Mat.Soukup@fda.hhs.gov) misspersp_reference_200.jpg Perspective Plot
Summary of All EG Parameters Mat Soukup (email: Mat.Soukup@fda.hhs.gov) EGall_Reference_200.png  
Systolic Blood Pressure (Main Profiles) Mat Soukup (email: Mat.Soukup@fda.hhs.gov) VSsbp_Reference_200.png Line Plot
Time Course of Lab Test Values, Individual Subject Robert Gordon (rgordon2@its.jnj.com) Gordon_TimeCourseTest_200.png Line Plot
Time to AE Occurrence Mat Soukup (email: Mat.Soukup@fda.hhs.gov)
Max Cherny (Max.2.Cherny@gsk.com)
Cherny_time_event_200.png Survival Plot
Number of topics: 36

Return to Top

Graph Types

Graph Type Title Contributor/Email Reference Image
  Reports by SOC Mat Soukup (email: Mat.Soukup@fda.hhs.gov) ReportsBySOC_referemce_200.jpg
  Heat map max.2.cherny@gsk.com
Sanjay Matange (email: Sanjay.Matange@sas.com)
Cherny_GGPLOT_Benefit_Risk_200.png
  Summary of All EG Parameters Mat Soukup (email: Mat.Soukup@fda.hhs.gov) EGall_Reference_200.png
  Individual QTc display A. Paredes, Antonio.Paredes@fda.hhs.gov
Max Cherny: Max2Cherny@gsk.com
Cherny_Rplot2_200.png
  Frequency Plot of the Change from Baseline in Alanine Aminotransferase by Visit Robert Gordon (rgordon2@its.jnj.com) Gordon_FreqPlot_200.png
  Cumulative Incidence for Alanine Aminotransferase (ALT): Elevations > 3 Times the Upper Limit of Normal Robert Gordon (rgordon2@its.jnj.com) GordonCumulIncidencePlot_200.png
Boxplot Boxplot of Two Treatment Groups Mat Soukup (email: Mat.Soukup@fda.hhs.gov) boxplotbasic_200.jpg
Boxplot Distribution of Alanine Aminotransferase (ALT) by Time and Treatment Robert Gordon (rgordon2@its.jnj.com)
Gordon_Distribution_ALT_200.png
Line Plot, Scatterplot, Other EG QTc Longitudinal Trend jianminlong@merck.com Long_QTc_longitudinal_200.png
Perspective Plot Sensitivity Analysis of Missing Data Mat Soukup (email: Mat.Soukup@fda.hhs.gov) misspersp_reference_200.jpg
Survival Plot Time to AE Occurrence Mat Soukup (email: Mat.Soukup@fda.hhs.gov)
Max Cherny (Max.2.Cherny@gsk.com)
Cherny_time_event_200.png
Survival Plot Basic Survival Plot Mat Soukup (email: Mat.Soukup@fda.hhs.gov) survplotRMS_200.jpg
Volcano Plots P-risk (Risk Difference) Plot of Treatment Emergent Adverse Events at PT Level Qi Jiang (email: Qjiang@amgen.com)
SAS code contributed by Haijun Ma and Jun Wei
Jiang_AE_Risk_200.png
Dotplot Most Frequent On-Therapy AE Sorted by Risk Difference FrankHarrell Figure11_AE_200.png
Dotplot Dotplot of Primary SOC Mat Soukup (email: Mat.Soukup@fda.hhs.gov)
Sanjay Matange (email: Sanjay.Matange@sas.com)
DotplotSOC_reference_200.png
Forest Plot Forest Plot of Hazard Ratios by Patient Subgroups Sanjay Matange (email: Sanjay.Matange@sas.com) Matange_ForestPlot_Pocock_200.png
Line Plot Liver Function Tests by Trial Day: At Risk Subjects Robert Gordon (rgordon2@its.jnj.com) Gordon_LFTTrialDay_200.png
Line Plot Time Course of Lab Test Values, Individual Subject Robert Gordon (rgordon2@its.jnj.com) Gordon_TimeCourseTest_200.png
Line Plot Systolic Blood Pressure (Main Profiles) Mat Soukup (email: Mat.Soukup@fda.hhs.gov) VSsbp_Reference_200.png
Line Plot Mean (and Mean Difference) of ALT (Alanine Aminotransferase) by Treatment : Profile Over Time Robert Gordon (rgordon2@its.jnj.com) Fig1_MeanALT_200.jpg
Line Plot Profile Plot: Mean QTc by Time and Treatment Rich Anziano (richard.j.anziano@pfizer.com)
Max Cherny (Max.2.Cherny@gsk.com)
QTc_Profiles_r200.png
Scatterplot Scatterplot Conditioned on Race Mat Soukup (email: Mat.Soukup@fda.hhs.gov) scattertrellis_reference_200.jpg
Scatterplot Liver Test Safety Panel Over Time, Baseline vs. On-study Robert Gordon (rgordon2@its.jnj.com)
Gordon_LiverTestSafety_200.png
Scatterplot Depicting Phase 2 Efficacy Results Mat Soukup (email: Mat.Soukup@fda.hhs.gov) DepictingPhaseTwo_Referemce_200.jpg
Scatterplot Lab Shift Plots: Baseline versus Maximum Susan Duke (susan.p.duke@gsk.com)
Max Cherny (Max.2.Cherny@gsk.com)
Cherny_t2t_200.png
Scatterplot Change from Baseline by Baseline: Categorical QTc Analysis Rich Anziano (richard.j.anziano@pfizer.com)
Max Cherny (Max.2.Cherny@gsk.com)
3_Baseline_QTc_hr1_200.png
Scatterplot Efficacy Across Sites Mat Soukup (email: Mat.Soukup@fda.hhs.gov) efficacybysite_Referemce_200.jpg
Scatterplot Efficacy by Subgroup Mat Soukup (email: Mat.Soukup@fda.hhs.gov) plottable_referemce_200.jpg
Scatterplot Lab Parameter Shift Plots, Baseline vs. Study Robert Gordon (rgordon2@its.jnj.com) Gordon_Shift_Plot_200.png
Scatterplot Local Reactions over Time Mat Soukup (email: Mat.Soukup@fda.hhs.gov) local_reference_200.png
Scatterplot Efficacy of T4N5 The Lancet Data - Code Expands Mat Soukup (email: Mat.Soukup@fda.hhs.gov) LancetEfficacy_reference_200.jpg
Scatterplot Diagnostic Plot of Linear Model Mat Soukup (email: Mat.Soukup@fda.hhs.gov) lmplot_reference_200.png
Scatterplot Scatter Plot of Maximum Transaminase versus Maximum Total Bilirubin Robert Gordon (rgordon2@its.jnj.com) MaxBilirubin_200.png
Scatterplot Scatterplot w/ Density and Smoothed Regression Mat Soukup (email: Mat.Soukup@fda.hhs.gov) scatterdensity_reference_200.jpg
Scatterplot QT Correction Comparison R.J. Anziano, Richard.J.Anziano@Pfizer.com DRAFT_Comparison_QT_200.png
Scatterplot HPA Axis Suppression Mat Soukup (email: Mat.Soukup@fda.hhs.gov) HPAaxis_Reference_200.jpg
Number of topics: 36

Return to Top

Software Program

Title Graph Displayed Contributor/Email Software Program
Basic Survival Plot   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Boxplot of Two Treatment Groups   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Change from Baseline by Baseline: Categorical QTc Analysis   Rich Anziano (richard.j.anziano@pfizer.com)
Max Cherny (Max.2.Cherny@gsk.com)
R
Cumulative Incidence for Alanine Aminotransferase (ALT): Elevations > 3 Times the Upper Limit of Normal   Robert Gordon (rgordon2@its.jnj.com) SAS
Depicting Phase 2 Efficacy Results   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Diagnostic Plot of Linear Model   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Distribution of Alanine Aminotransferase (ALT) by Time and Treatment   Robert Gordon (rgordon2@its.jnj.com)
SAS
Dotplot of Primary SOC   Mat Soukup (email: Mat.Soukup@fda.hhs.gov)
Sanjay Matange (email: Sanjay.Matange@sas.com)
R, SAS
EG QTc Longitudinal Trend   jianminlong@merck.com SAS
Efficacy Across Sites   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Efficacy by Subgroup   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Efficacy of T4N5 The Lancet Data - Code Expands   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Forest Plot of Hazard Ratios by Patient Subgroups   Sanjay Matange (email: Sanjay.Matange@sas.com) SAS
Frequency Plot of the Change from Baseline in Alanine Aminotransferase by Visit   Robert Gordon (rgordon2@its.jnj.com) SAS
HPA Axis Suppression   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Heat map   max.2.cherny@gsk.com
Sanjay Matange (email: Sanjay.Matange@sas.com)
R, SAS
Individual QTc display   A. Paredes, Antonio.Paredes@fda.hhs.gov
Max Cherny: Max2Cherny@gsk.com
R
Lab Parameter Shift Plots, Baseline vs. Study   Robert Gordon (rgordon2@its.jnj.com) SAS
Lab Shift Plots: Baseline versus Maximum   Susan Duke (susan.p.duke@gsk.com)
Max Cherny (Max.2.Cherny@gsk.com)
SAS, other
Liver Function Tests by Trial Day: At Risk Subjects   Robert Gordon (rgordon2@its.jnj.com) SAS
Liver Test Safety Panel Over Time, Baseline vs. On-study   Robert Gordon (rgordon2@its.jnj.com)
SAS
Local Reactions over Time   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Mean (and Mean Difference) of ALT (Alanine Aminotransferase) by Treatment : Profile Over Time   Robert Gordon (rgordon2@its.jnj.com) SAS
Most Frequent On-Therapy AE Sorted by Risk Difference   FrankHarrell R, SAS
P-risk (Risk Difference) Plot of Treatment Emergent Adverse Events at PT Level   Qi Jiang (email: Qjiang@amgen.com)
SAS code contributed by Haijun Ma and Jun Wei
SAS
Profile Plot: Mean QTc by Time and Treatment   Rich Anziano (richard.j.anziano@pfizer.com)
Max Cherny (Max.2.Cherny@gsk.com)
R, SAS
QT Correction Comparison   R.J. Anziano, Richard.J.Anziano@Pfizer.com  
Reports by SOC   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Scatter Plot of Maximum Transaminase versus Maximum Total Bilirubin   Robert Gordon (rgordon2@its.jnj.com) SAS
Scatterplot Conditioned on Race   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Scatterplot w/ Density and Smoothed Regression   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Sensitivity Analysis of Missing Data   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Summary of All EG Parameters   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) SAS
Systolic Blood Pressure (Main Profiles)   Mat Soukup (email: Mat.Soukup@fda.hhs.gov) R
Time Course of Lab Test Values, Individual Subject   Robert Gordon (rgordon2@its.jnj.com) SAS
Time to AE Occurrence   Mat Soukup (email: Mat.Soukup@fda.hhs.gov)
Max Cherny (Max.2.Cherny@gsk.com)
R, SAS
Number of topics: 36

Return to Top

Return to Statistical Graphics Home

Topic revision: r25 - 24 Oct 2013 - 11:34:48 - MatSoukup
 

Copyright & by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding CTSPedia? Send feedback